Colorectal cancer is the fourth most commonly diagnosed cancer and the second leading cause of cancer-related deaths in the U.S. [1] . Almost a third of patients already have metastatic disease at diagnosis, and half the patients diagnosed and resected with early-stage disease subsequently develop metastases [2] . Nearly all patients with metastatic cancer die of their disease.
Colorectal cancer is the fourth most commonly diagnosed cancer and the second leading cause of cancer-related deaths in the U.S. [1] . Almost a third of patients already have metastatic disease at diagnosis, and half the patients diagnosed and resected with early-stage disease subsequently develop metastases [2] . Nearly all patients with metastatic cancer die of their disease.
For many decades, the only effective first-line treatment for metastatic colorectal cancer remained fluorouracil (FU). Subsequently, coadministration of FU with leucovorin (LV) increased response rates and time to progression, but only marginally improved overall survival [3, 4] . Various attempts were made to optimize this regimen using different doses and schedules, but although these modifications revealed interesting differences in their side-effect profiles, they failed to deliver noticeably improved clinical benefit. Similarly, capecitabine (Xeloda ® ; Hoffmann-La Roche Inc., Nutley, NJ, http://www.roche.us), an oral FU prodrug, while more convenient and with a more acceptable sideeffect profile, has not increased survival over that achieved with i.v. regimens [5, 6] .
As oncology entered the 21st Century, however, the deadlock that had characterized metastatic colorectal cancer for so many years began to shift. Combinations of newer agents with FU in the first-line setting for this hitherto intractable disease have improved survival. The first of these recent arrivals was the topoisomerase-I inhibitor, irinotecan (Camptosar ® ; Pfizer Pharmaceuticals Inc., New York, NY, http://www.pfizer.com). When added to bolus or infusional FU, irinotecan results in a greater overall survival rate and a longer time to progression than FU/LV alone [7, 8] . However, this agent has significant toxicities, which can occasionally be severe, particularly when given with bolus FU.
The second agent to show a survival benefit when added to FU in the first-line setting was oxaliplatin (Eloxatin ® ; Sanofi-Synthélabo Inc., New York, NY, http://www.sanofisynthelabo.us), a third-generation platinum compound. In the first such trial, results were encouraging, although the improvement in overall survival was not statistically higher than with FU/LV; however, it should be noted that crossover may have obscured a small impact on overall survival [9] . More recently, a bigger phase III study of oxaliplatin combined with a bolus/infusional FU regimen (FOLFOX4) produced a superior response rate, time to progression, and overall survival compared with the bolus irinotecan/FU/LV (IFL) regimen [10] . Based on these data, FOLFOX4 was approved in the U.S. for the first-line treatment of colorectal cancer. However, oxaliplatin also carries a significant toxicity profile-one of these toxicities (namely neuropathy) is cumulative and often necessitates treatment interruption after 6 months.
The year 2004 also saw the approval of two new biologic agents for colorectal cancer-bevacizumab (Avastin So could adding a biologic agent to these chemotherapeutic regimens be the key to longer survival for patients with metastatic colorectal cancer? Results from early trials are encouraging. In a pivotal 923-patient study evaluating the addition of bevacizumab to IFL, bevacizumab conferred superior survival, time to progression, and response rates that were both clinically and statistically significant [11] . Overall survival for patients treated with IFL/bevacizumab was 20.3 months-almost double the survival with FU/LV alone only 5 years ago [3] . Notably, this result was achieved with a chemotherapy regimen no longer considered the standard of care and in the relative absence of effective second-line therapy. For those patients who progressed and did receive oxaliplatin-based chemotherapy, the median survival time was even better, at approximately 25 months [11] . Interestingly, this suggests that second-line therapies have an impact on overall survival. Indeed, a recent study showed that median overall survival correlates significantly with the percentage of patients receiving FU/LV, irinotecan, and oxaliplatin over their disease course. This suggests that all these agents should be made available to all patients with metastatic colorectal cancer.
Importantly, a combined analysis of studies assessing the addition of bevacizumab to FU/LV chemotherapy without irinotecan has also shown advantages in both overall and progression-free survival times compared with FU or IFL chemotherapies [12] . Thus, bevacizumab plus FU/LV benchmarks well in its activity compared with irinotecan plus FU/LV-but with a much more manageable sideeffect profile. With few, if any, overlapping toxicities with traditional chemotherapies, the primary side effect of bevacizumab is hypertension [11] . This is easily managed, requiring the addition or adjustment of oral antihypertensives in only 11% of patients. A warning was issued recently to physicians by the manufacturer and the U.S. Food and Drug Administration regarding an estimated overall risk rate of up to 5% for serious arterial thrombotic events associated with the use of bevacizumab, although this information is included in the drug's packaging. While many experts recognize the benefits of the use of bevacizumab in colorectal cancer patients, as with any medication, the risk-benefit ratio must be carefully considered on an individual patient basis.
While bevacizumab can be safely combined with FOL-FOX4 [13] , efficacy data with this combination are not yet available. Data from the Eastern Cooperative Oncology Group have recently been reported and showed an improved survival for patients in the FOLFOX+bevacizumab arm compared to FOLFOX alone [14] . Trials are also under way to evaluate bevacizumab in the adjuvant setting.
Cetuximab, a monoclonal antibody directed against the human epidermal growth factor receptor (HER-1/EGFR), was approved in 2004 based on its activity in combination with irinotecan in the second-and third-line treatment of patients who had recently progressed on irinotecan or an irinotecan-containing regimen. Although cetuximab also showed some single-agent activity in this setting, a combination of irinotecan plus cetuximab resulted in a higher response rate (22.9% versus 10.8%) and a longer time to progression (4.1 versus 1.5 months) compared with cetuximab alone. Although no survival benefit was observed, this finding must be interpreted with caution as this was a phase II trial and insufficiently powered to determine survival impact [15] . Clinical trials are now being done to study cetuximab in the first-and second-line settings for patients who have not received prior irinotecan. The primary toxicity of cetuximab is an acneiform rash, which is common and may correlate with antitumor activity [16] .
Compared with only a short time ago when the only treatment option was FU/LV, there are now five additional agents approved for use in metastatic colorectal cancer. Each has completed a pivotal registration study to demonstrate New Combination Regimens in Metastatic Colorectal Cancer activity and clinical value. To try to further improve the clinical usefulness of these agents, trials evaluating alternative combinations and sequences are now in progress [17] . We hope that ongoing trials will help us understand further how agents should be used to achieve maximum clinical benefit. In the last 5 years, we have seen the addition of several new treatments for a disease that was once considered untreatable, and survival has nearly doubled in that time; there are now five additional agents approved for use in metastatic colorectal cancer, with median survivals now approaching 2 years (Fig. 1 ). These recent advances should give us-and our patients-justifiable hope that further advances are not only possible, but also likely. However, the static overall mortality rate reminds us that there is still much progress to be made in the treatment of this disease.
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